Kohei Kaku, Hiroyuki Isaka, Taishi Sakatani, Junko Toyoshima. Diabetes Obes Metab 2019
Times Cited: 20
Times Cited: 20
Times Cited
Times Co-cited
Similarity
Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.
Robert R Henry, Payal Thakkar, Cindy Tong, David Polidori, Maria Alba. Diabetes Care 2015
Robert R Henry, Payal Thakkar, Cindy Tong, David Polidori, Maria Alba. Diabetes Care 2015
60
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
60
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
55
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
50
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
45
Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
Kohei Kaku, Hiroyuki Isaka, Junko Toyoshima, Taishi Sakatani. Diabetes Obes Metab 2019
Kohei Kaku, Hiroyuki Isaka, Junko Toyoshima, Taishi Sakatani. Diabetes Obes Metab 2019
70
Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol.
Satish K Garg, Anne L Peters, John B Buse, Thomas Danne. Diabetes Technol Ther 2018
Satish K Garg, Anne L Peters, John B Buse, Thomas Danne. Diabetes Technol Ther 2018
35
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
30
Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.
Eiichi Araki, Hirotaka Watada, Yasuko Uchigata, Osamu Tomonaga, Hitomi Fujii, Hiroshi Ohashi, Tadashi Okabe, Michiko Asano, Fredrik Thoren, Hyosung Kim,[...]. Diabetes Obes Metab 2020
Eiichi Araki, Hirotaka Watada, Yasuko Uchigata, Osamu Tomonaga, Hitomi Fujii, Hiroshi Ohashi, Tadashi Okabe, Michiko Asano, Fredrik Thoren, Hyosung Kim,[...]. Diabetes Obes Metab 2020
37
HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
30
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
30
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
30
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
25
Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.
Tomohide Yamada, Nobuhiro Shojima, Hisashi Noma, Toshimasa Yamauchi, Takashi Kadowaki. Diabetes Obes Metab 2018
Tomohide Yamada, Nobuhiro Shojima, Hisashi Noma, Toshimasa Yamauchi, Takashi Kadowaki. Diabetes Obes Metab 2018
25
Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
Akira Shimada, Toshiaki Hanafusa, Atsutaka Yasui, Ganghyuck Lee, Yusuke Taneda, Akiko Sarashina, Kosuke Shiki, Jyothis George, Nima Soleymanlou, Jan Marquard. Diabetes Obes Metab 2018
Akira Shimada, Toshiaki Hanafusa, Atsutaka Yasui, Ganghyuck Lee, Yusuke Taneda, Akiko Sarashina, Kosuke Shiki, Jyothis George, Nima Soleymanlou, Jan Marquard. Diabetes Obes Metab 2018
25
Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Jingli Lu, Lijuan Tang, Haiyang Meng, Junjie Zhao, Yan Liang. Diabetes Metab Res Rev 2019
Jingli Lu, Lijuan Tang, Haiyang Meng, Junjie Zhao, Yan Liang. Diabetes Metab Res Rev 2019
25
A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study.
A Kashiwagi, H Takahashi, H Ishikawa, S Yoshida, K Kazuta, A Utsuno, E Ueyama. Diabetes Obes Metab 2015
A Kashiwagi, H Takahashi, H Ishikawa, S Yoshida, K Kazuta, A Utsuno, E Ueyama. Diabetes Obes Metab 2015
20
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
20
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
D M Nathan, S Genuth, J Lachin, P Cleary, O Crofford, M Davis, L Rand, C Siebert. N Engl J Med 1993
D M Nathan, S Genuth, J Lachin, P Cleary, O Crofford, M Davis, L Rand, C Siebert. N Engl J Med 1993
20
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
20
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
20
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.
Tadej Battelino, Thomas Danne, Richard M Bergenstal, Stephanie A Amiel, Roy Beck, Torben Biester, Emanuele Bosi, Bruce A Buckingham, William T Cefalu, Kelly L Close,[...]. Diabetes Care 2019
Tadej Battelino, Thomas Danne, Richard M Bergenstal, Stephanie A Amiel, Roy Beck, Torben Biester, Emanuele Bosi, Bruce A Buckingham, William T Cefalu, Kelly L Close,[...]. Diabetes Care 2019
20
Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
20
The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.
Helena W Rodbard, Anne L Peters, April Slee, Anjun Cao, Shana B Traina, Maria Alba. Diabetes Care 2017
Helena W Rodbard, Anne L Peters, April Slee, Anjun Cao, Shana B Traina, Maria Alba. Diabetes Care 2017
20
Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis.
Dana El Masri, Samiran Ghosh, Linda A Jaber. Diabetes Res Clin Pract 2018
Dana El Masri, Samiran Ghosh, Linda A Jaber. Diabetes Res Clin Pract 2018
20
Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
20
SGLT inhibitor adjunct therapy in type 1 diabetes.
Rory J McCrimmon, Robert R Henry. Diabetologia 2018
Rory J McCrimmon, Robert R Henry. Diabetologia 2018
20
Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
Ronald M Goldenberg, Jeremy D Gilbert, Irene M Hramiak, Vincent C Woo, Bernard Zinman. Diabetes Obes Metab 2019
Ronald M Goldenberg, Jeremy D Gilbert, Irene M Hramiak, Vincent C Woo, Bernard Zinman. Diabetes Obes Metab 2019
20
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Elena Paschetta. BMJ 2019
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Elena Paschetta. BMJ 2019
20
Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.
Bruce A Perkins, David Z I Cherney, Helen Partridge, Nima Soleymanlou, Holly Tschirhart, Bernard Zinman, Nora M Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C Broedl,[...]. Diabetes Care 2014
Bruce A Perkins, David Z I Cherney, Helen Partridge, Nima Soleymanlou, Holly Tschirhart, Bernard Zinman, Nora M Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C Broedl,[...]. Diabetes Care 2014
15
Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus.
Atsunori Kashiwagi, Kenichi Kazuta, Satoshi Yoshida, Itsuro Nagase. J Diabetes Investig 2014
Atsunori Kashiwagi, Kenichi Kazuta, Satoshi Yoshida, Itsuro Nagase. J Diabetes Investig 2014
15
Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.
Hisamitsu Ishihara, Susumu Yamaguchi, Ikko Nakao, Akira Okitsu, Seitaro Asahina. Diabetes Obes Metab 2016
Hisamitsu Ishihara, Susumu Yamaguchi, Ikko Nakao, Akira Okitsu, Seitaro Asahina. Diabetes Obes Metab 2016
15
Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).
Susanne Famulla, Thomas R Pieber, Jens Eilbracht, Dietmar Neubacher, Nima Soleymanlou, Hans J Woerle, Uli C Broedl, Stefan Kaspers. Diabetes Technol Ther 2017
Susanne Famulla, Thomas R Pieber, Jens Eilbracht, Dietmar Neubacher, Nima Soleymanlou, Hans J Woerle, Uli C Broedl, Stefan Kaspers. Diabetes Technol Ther 2017
15
Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
Chantal Mathieu, Paresh Dandona, Moshe Phillip, Tal Oron, Marcus Lind, Lars Hansen, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2019
Chantal Mathieu, Paresh Dandona, Moshe Phillip, Tal Oron, Marcus Lind, Lars Hansen, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2019
15
SGLT2 Inhibitors May Predispose to Ketoacidosis.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J Clin Endocrinol Metab 2015
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J Clin Endocrinol Metab 2015
15
The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis.
Jiao Chen, Fang Fan, J Y Wang, Yang Long, C L Gao, R C Stanton, Yong Xu. Sci Rep 2017
Jiao Chen, Fang Fan, J Y Wang, Yang Long, C L Gao, R C Stanton, Yong Xu. Sci Rep 2017
15
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
15
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018.
Nicole C Foster, Roy W Beck, Kellee M Miller, Mark A Clements, Michael R Rickels, Linda A DiMeglio, David M Maahs, William V Tamborlane, Richard Bergenstal, Elizabeth Smith,[...]. Diabetes Technol Ther 2019
Nicole C Foster, Roy W Beck, Kellee M Miller, Mark A Clements, Michael R Rickels, Linda A DiMeglio, David M Maahs, William V Tamborlane, Richard Bergenstal, Elizabeth Smith,[...]. Diabetes Technol Ther 2019
15
Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study.
Torben Biester, Ido Muller, Thekla von dem Berge, Eran Atlas, Revital Nimri, Moshe Phillip, Tadej Battelino, Natasa Bratina, Klemen Dovc, Markus F Scheerer,[...]. Diabetes Obes Metab 2021
Torben Biester, Ido Muller, Thekla von dem Berge, Eran Atlas, Revital Nimri, Moshe Phillip, Tadej Battelino, Natasa Bratina, Klemen Dovc, Markus F Scheerer,[...]. Diabetes Obes Metab 2021
23
Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group.
. Diabetes Care 1988
. Diabetes Care 1988
15
BMI, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes: Findings Against an Obesity Paradox.
Jon Edqvist, Araz Rawshani, Martin Adiels, Lena Björck, Marcus Lind, Ann-Marie Svensson, Sofia Gudbjörnsdottir, Naveed Sattar, Annika Rosengren. Diabetes Care 2019
Jon Edqvist, Araz Rawshani, Martin Adiels, Lena Björck, Marcus Lind, Ann-Marie Svensson, Sofia Gudbjörnsdottir, Naveed Sattar, Annika Rosengren. Diabetes Care 2019
15
Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study.
Kohei Kaku, Hiroyuki Isaka, Taishi Sakatani, Junko Toyoshima. J Diabetes Investig 2020
Kohei Kaku, Hiroyuki Isaka, Taishi Sakatani, Junko Toyoshima. J Diabetes Investig 2020
75
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
Per-Henrik Groop, Paresh Dandona, Moshe Phillip, Pieter Gillard, Steven Edelman, Johan Jendle, John Xu, Markus F Scheerer, Fredrik Thoren, Nayyar Iqbal,[...]. Lancet Diabetes Endocrinol 2020
Per-Henrik Groop, Paresh Dandona, Moshe Phillip, Pieter Gillard, Steven Edelman, Johan Jendle, John Xu, Markus F Scheerer, Fredrik Thoren, Nayyar Iqbal,[...]. Lancet Diabetes Endocrinol 2020
20
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members.
Jian Chen, Sandy Williams, Samantha Ho, Howard Loraine, Deborah Hagan, Jean M Whaley, John N Feder. Diabetes Ther 2010
Jian Chen, Sandy Williams, Samantha Ho, Howard Loraine, Deborah Hagan, Jean M Whaley, John N Feder. Diabetes Ther 2010
10
On type 1 diabetes mellitus pathogenesis.
Stavroula A Paschou, Nektaria Papadopoulou-Marketou, George P Chrousos, Christina Kanaka-Gantenbein. Endocr Connect 2018
Stavroula A Paschou, Nektaria Papadopoulou-Marketou, George P Chrousos, Christina Kanaka-Gantenbein. Endocr Connect 2018
10
Japanese Clinical Practice Guideline for Diabetes 2016.
Masakazu Haneda, Mitsuhiko Noda, Hideki Origasa, Hiroshi Noto, Daisuke Yabe, Yukihiro Fujita, Atsushi Goto, Tatsuya Kondo, Eiichi Araki. J Diabetes Investig 2018
Masakazu Haneda, Mitsuhiko Noda, Hideki Origasa, Hiroshi Noto, Daisuke Yabe, Yukihiro Fujita, Atsushi Goto, Tatsuya Kondo, Eiichi Araki. J Diabetes Investig 2018
10
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Atsunori Kashiwagi, Satoshi Yoshida, Ichiro Nakamura, Kenichi Kazuta, Eiji Ueyama, Hideyuki Takahashi, Hayato Satomi, Yoshinori Kosakai, Kosei Kawamuki. J Diabetes Investig 2016
Atsunori Kashiwagi, Satoshi Yoshida, Ichiro Nakamura, Kenichi Kazuta, Eiji Ueyama, Hideyuki Takahashi, Hayato Satomi, Yoshinori Kosakai, Kosei Kawamuki. J Diabetes Investig 2016
10
Type 1 diabetes, metabolic syndrome and cardiovascular risk.
Juan J Chillarón, Juana A Flores Le-Roux, David Benaiges, Juan Pedro-Botet. Metabolism 2014
Juan J Chillarón, Juana A Flores Le-Roux, David Benaiges, Juan Pedro-Botet. Metabolism 2014
10
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Atsuo Tahara, Eiji Kurosaki, Masanori Yokono, Daisuke Yamajuku, Rumi Kihara, Yuka Hayashizaki, Toshiyuki Takasu, Masakazu Imamura, Li Qun, Hiroshi Tomiyama,[...]. Naunyn Schmiedebergs Arch Pharmacol 2012
Atsuo Tahara, Eiji Kurosaki, Masanori Yokono, Daisuke Yamajuku, Rumi Kihara, Yuka Hayashizaki, Toshiyuki Takasu, Masakazu Imamura, Li Qun, Hiroshi Tomiyama,[...]. Naunyn Schmiedebergs Arch Pharmacol 2012
10
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.